Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease

Background Neuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies. Objective We sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways. Methods We identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than −2.0, a false-discovery rate corrected p -value less than 0.05, and evidence in transgenic mouse models or AD clinical trials. Results We found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models. Conclusions We provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease
Published
2026-11-18
DOI
https://doi.org/10.1177/13872877261507113
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease

Davis Cammann, Feixiong Cheng, Jingchun Chen, Jeffrey L. Cummings et al.
2 links
Journal of Alzheimer s Disease
Alzheimer's disease research and treatments
article

Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease

Davis Cammann, Feixiong Cheng, Jingchun Chen, Jeffrey L. Cummings, Yadi Zhou
article en

Abstract

Background Neuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies. Objective We sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways. Methods We identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than −2.0, a false-discovery rate corrected p -value less than 0.05, and evidence in transgenic mouse models or AD clinical trials. Results We found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models. Conclusions We provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.

Journal of Alzheimer s Disease
Cleveland Clinic (US), University of Nevada, Las Vegas (US), Cleveland Clinic Research (US)
National Institutes of Health, National Institute on Aging, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, Mountain West Clinical and Translational Research Infrastructure Network Program
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon